In-hospital cardiac arrest

院内心脏骤停
  • 文章类型: Journal Article
    (1) Background: Telemetry units allow the continuous monitoring of vital signs and ECG of patients. Such physiological indicators work as the digital signatures and biomarkers of disease that can aid in detecting abnormalities that appear before cardiac arrests (CAs). This review aims to identify the vital sign abnormalities measured by telemetry systems that most accurately predict CAs. (2) Methods: We conducted a systematic review using PubMed, Embase, Web of Science, and MEDLINE to search studies evaluating telemetry-detected vital signs that preceded in-hospital CAs (IHCAs). (3) Results and Discussion: Out of 45 studies, 9 met the eligibility criteria. Seven studies were case series, and 2 were case controls. Four studies evaluated ECG parameters, and 5 evaluated other physiological indicators such as blood pressure, heart rate, respiratory rate, oxygen saturation, and temperature. Vital sign changes were highly frequent among participants and reached statistical significance compared to control subjects. There was no single vital sign change pattern found in all patients. ECG alarm thresholds may be adjustable to reduce alarm fatigue. Our review was limited by the significant dissimilarities of the studies on methodology and objectives. (4) Conclusions: Evidence confirms that changes in vital signs have the potential for predicting IHCAs. There is no consensus on how to best analyze these digital biomarkers. More rigorous and larger-scale prospective studies are needed to determine the predictive value of telemetry-detected vital signs for IHCAs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Meta-Analysis
    目的:严重急性呼吸系统综合症冠状病毒2(SARS-CoV-2)引起了全球大流行,并对整个医疗保健系统产生了负面影响。了解COVID-19对院内心脏骤停(IHCA)结局的影响,一项系统评价和荟萃分析的研究旨在比较遭受心脏骤停的成年患者的大流行前和大流行内时期,此外,通过进行与COVID-19阳性和阴性患者在同一组患者中。
    方法:为评估COVID-19对IHCA结局的影响,进行了系统评价和荟萃分析。Pubmed(MEDLINE),Scopus,Embase,WebofScience,和Cochrane数据库搜索了2020年1月1日至2023年4月8日发表的文章。
    结果:在COVID-19前和COVID-19大流行期IHCA患者中自发循环事件的复发各不相同,分别为64.0%和60.0%,分别(OR=1.23;95CI:1.19至1.26;p<0.001)。再次逮捕发生率为4.5%vs.4.9%,分别(OR=1.24;95CI:1.00至1.53;p=0.05)。出院生存率(SHD)为25.1%,而COVID-19期间为20.9%(OR=1.17;95CI:0.96至1.41;p=0.12)。在COVID-19期间,COVID-19阳性患者的SHD为14.0%,而非COVID-19患者的SHD为25.9%(OR=0.72;95CI:0.28至1.86;p=0.50)。COVID-19阳性的30天生存率与阴性患者为62.6%vs.58.3%,分别(OR=0.99;95CI:0.23至4.24;p=0.99)。
    结论:SARS-CoV-2感染患者的ROSC和SDH发生率降低,以及在COVID-19期间较差的神经系统结局和住院再逮捕增加。然而,SARS-CoV-2阳性和阴性患者的30天生存率相似.
    OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic and had a negative impact on the entire health care system. To understand the effect of COVID-19 on outcomes of in-hospital cardiac arrest (IHCA), a systematic review and meta-analysis of studies was designed to compare the pre- and intra-pandemic periods of adult patients who suffered cardiac arrest, and additionally by performing a sub-analysis related to COVID-19 positive vs. negative patients in the same group of patients.
    METHODS: To evaluate the impact of COVID-19 on IHCA outcomes a systematic review and meta-analysis was performed. Pubmed (MEDLINE), Scopus, Embase, Web of Science, and Cochrane database were searched for articles published from 1 January 2020 - 8 April 2023.
    RESULTS: Return of spontaneous circulation events among IHCA patients in pre-COVID-19 and COVID-19 pandemic periods varied and amounted to 64.0% vs. 60.0%, respectively (OR=1.23; 95%CI: 1.19 to 1.26; p<0.001). Re-arrest occurrence was 4.5% vs. 4.9%, respectively (OR=1.24; 95%CI: 1.00 to 1.53; p=0.05). Survival to hospital discharge (SHD) was 25.1% compared to 20.9% for COVID-19 period (OR = 1.17; 95%CI: 0.96 to 1.41; p=0.12). During the COVID-19 period, SHD in COVID-19 positive patients was 14.0% compared to 25.9% for patients without COVID-19 (OR=0.72; 95%CI: 0.28 to 1.86; p=0.50). 30-day survival rate among COVID-19 positive vs. negative patients was 62.6% vs. 58.3%, respectively (OR =0.99; 95%CI: 0.23 to 4.24; p=0.99).
    CONCLUSIONS: Patients with SARS-CoV-2 infection had reduced rates of ROSC and SDH, as well as poorer neurologic outcomes and increased in hospital re-arrests during the COVID-19 period. However, the 30-day survival rate was similar in SARS-CoV-2 positive and negative patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:一些小型单机构研究报告了COVID-19患者院内心脏骤停(IHCA)后的结果;然而,没有大型研究将COVID-19IHCA与非COVID-19IHCA进行对比。这项研究的目的是比较COVID-19和非COVID-19患者在IHCA治疗后的结果。
    方法:我们使用预定义的搜索词和适当的布尔运算符搜索数据库。直到2022年8月发表的所有相关文章都包括在分析中。根据系统评价和荟萃分析(PRISMA)指南的首选报告项目进行系统评价和荟萃分析。使用具有95%置信区间(CI)的比值比来衡量效果。
    结果:在筛选的855项研究中,6项研究包括27,453例IHCA患者(63.84%男性)和20,766例(59.7%男性)无COVID-19的研究。COVID-19患者的IHCA实现自主循环恢复(ROSC)的几率较低(OR:0.66,95%CI:0.62-0.70)。同样,COVID-19患者在IHCA后30天死亡的几率更高(OR:2.26,95%CI:2.08-2.45),并且由于可电击心律而心脏骤停的几率降低了45%(OR:0.55,95%CI:0.50-0.60)(9.59%vs.16.39%)。COVID-19患者较少接受针对性体温管理(TTM)或冠状动脉造影;然而,与没有COVID-19感染的患者相比,他们更常见的是插管和血管加压药治疗.
    结论:这项荟萃分析显示,与非COVID-19IHCA相比,COVID-19IHCA具有更高的死亡率和更低的ROSC发生率。COVID-19是IHCA患者预后不良的独立危险因素。
    BACKGROUND: Outcomes following in-hospital cardiac arrest (IHCA) in patients with COVID-19 have been reported by several small single-institutional studies; however, there are no large studies contrasting COVID-19 IHCA with non-COVID-19 IHCA. The objective of this study was to compare the outcomes following IHCA between COVID-19 and non-COVID-19 patients.
    METHODS: We searched databases using predefined search terms and appropriate Boolean operators. All the relevant articles published till August 2022 were included in the analyses. The systematic review and meta-analysis were conducted as per Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. An odds ratio with a 95% confidence interval (CI) was used to measure effects.
    RESULTS: Among 855 studies screened, 6 studies with 27,453 IHCA patients (63.84% male) with COVID-19 and 20,766 (59.7% male) without COVID-19 were included in the analysis. IHCA among patients with COVID-19 has lower odds of achieving return of spontaneous circulation (ROSC) (OR: 0.66, 95% CI: 0.62-0.70). Similarly, patients with COVID-19 have higher odds of 30-day mortality following IHCA (OR: 2.26, 95% CI: 2.08-2.45) and have 45% lower odds of cardiac arrest because of a shockable rhythm (OR: 0.55, 95% CI: 0.50-0.60) (9.59% vs. 16.39%). COVID-19 patients less commonly underwent targeted temperature management (TTM) or coronary angiography; however, they were more commonly intubated and on vasopressor therapy as compared to patients who did not have a COVID-19 infection.
    CONCLUSIONS: This meta-analysis showed that IHCA with COVID-19 has a higher mortality and lower rates of ROSC compared with non-COVID-19 IHCA. COVID-19 is an independent risk factor for poor outcomes in IHCA patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    背景:已经发表了几种院内心脏骤停(IHCA)后生存的预测模型,但没有模型性能和外部验证的概述。我们使用停搏前因素对IHCA尝试复苏的结果预测的可用预后模型进行了系统评价,以通过改善的结果预测来增强临床决策。
    方法:本系统综述遵循CHARMS和PRISMA指南。Medline,Embase,截至2021年10月,搜索了WebofScience。研究发展,纳入了针对IHCA尝试复苏的任何潜在临床结局更新或验证具有停搏前因素的预测模型.根据PROBAST检查表对研究进行了严格评估。进行随机效应荟萃分析以汇集外部验证模型的AUROC值。
    结果:在筛选的2678篇初始文章中,这项系统评价包括33项研究:16项模型开发研究,5项模型更新研究和12项模型验证研究。最常见的逮捕前因素包括年龄,功能状态,(转移性)恶性肿瘤,心脏病,脑血管事件,呼吸,肾或肝功能不全,低血压和败血症。只有六个开发的模型在外部人群中得到了独立验证。GO-FAR评分表现最佳,合并AUROC为0.78(95%CI0.69-0.85),PAM的0.59(95CI0.50-0.68)和PAR的0.62(95%CI0.49-0.74)。
    结论:已经发表了几种用于IHCA尝试复苏后临床结果的预后模型。大多数都有中等程度的偏差风险,没有经过外部验证。GO-FAR评分显示出最可接受的性能。未来的研究应该集中在更新现有的模型,用于临床设置,特别是逮捕前的咨询。系统审查注册PROSPEROCRD42021269235。2021年7月21日注册。
    Several prediction models of survival after in-hospital cardiac arrest (IHCA) have been published, but no overview of model performance and external validation exists. We performed a systematic review of the available prognostic models for outcome prediction of attempted resuscitation for IHCA using pre-arrest factors to enhance clinical decision-making through improved outcome prediction.
    This systematic review followed the CHARMS and PRISMA guidelines. Medline, Embase, Web of Science were searched up to October 2021. Studies developing, updating or validating a prediction model with pre-arrest factors for any potential clinical outcome of attempted resuscitation for IHCA were included. Studies were appraised critically according to the PROBAST checklist. A random-effects meta-analysis was performed to pool AUROC values of externally validated models.
    Out of 2678 initial articles screened, 33 studies were included in this systematic review: 16 model development studies, 5 model updating studies and 12 model validation studies. The most frequently included pre-arrest factors included age, functional status, (metastatic) malignancy, heart disease, cerebrovascular events, respiratory, renal or hepatic insufficiency, hypotension and sepsis. Only six of the developed models have been independently validated in external populations. The GO-FAR score showed the best performance with a pooled AUROC of 0.78 (95% CI 0.69-0.85), versus 0.59 (95%CI 0.50-0.68) for the PAM and 0.62 (95% CI 0.49-0.74) for the PAR.
    Several prognostic models for clinical outcome after attempted resuscitation for IHCA have been published. Most have a moderate risk of bias and have not been validated externally. The GO-FAR score showed the most acceptable performance. Future research should focus on updating existing models for use in clinical settings, specifically pre-arrest counselling. Systematic review registration PROSPERO CRD42021269235. Registered 21 July 2021.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    冷却的既定好处以及安全和精确诱导的复杂方法的发展,保持,监视器,和反向低温导致了目标温度管理(TTM)的发展。人类受试者的早期试验表明,与心脏骤停幸存者的正常体温相比,低温可带来更好的神经系统预后。导致指南建议在该患者人群中进行靶向低温治疗。多项研究试图探索和比较低体温对不同亚组患者的益处,例如院外心脏骤停的幸存者与院内心脏骤停的幸存者,以及最初可电击和不可电击节奏的幸存者。更大和更近的试验表明,靶向低温和靶向正常体温的患者在神经系统预后方面没有统计学上的显著差异;此外,积极降温与多种全身并发症的发生率较高相关.根据这些数据,在最近的时间里,时间趋势倾向于使用宽松的温度目标。目前的指南建议为使用TTM的患者选择并保持32至36°C之间的恒定目标温度(强烈建议,中等质量的证据),在实现自主循环和气道恢复后尽快,呼吸(包括机械通气),循环稳定。较低温度(32-34°C)与较高温度(36°C)的相对优势仍然未知,进一步的研究可能有助于阐明这一点。任何昏迷的心脏骤停幸存者(定义为对外部刺激的不可唤醒的无反应性)应被视为TTM的候选人,无论最初的表现节律如何,选择有针对性的低温与有针对性的正常体温的决定应视具体情况而定。
    The established benefits of cooling along with development of sophisticated methods to safely and precisely induce, maintain, monitor, and reverse hypothermia have led to the development of targeted temperature management (TTM). Early trials in human subjects showed that hypothermia conferred better neurological outcomes when compared to normothermia among survivors of cardiac arrest, leading to guidelines recommending targeted hypothermia in this patient population. Multiple studies have sought to explore and compare the benefit of hypothermia in various subgroups of patients, such as survivors of out-of-hospital cardiac arrest versus in-hospital cardiac arrest, and survivors of an initial shockable versus non-shockable rhythm. Larger and more recent trials have shown no statistically significant difference in neurological outcomes between patients with targeted hypothermia and targeted normothermia; further, aggressive cooling is associated with a higher incidence of multiple systemic complications. Based on this data, temporal trends have leaned towards using a lenient temperature target in more recent times. Current guidelines recommend selecting and maintaining a constant target temperature between 32 and 36 °C for those patients in whom TTM is used (strong recommendation, moderate-quality evidence), as soon as possible after return of spontaneous circulation is achieved and airway, breathing (including mechanical ventilation), and circulation are stabilized. The comparative benefit of lower (32-34 °C) versus higher (36 °C) temperatures remains unknown, and further research may help elucidate this. Any survivor of cardiac arrest who is comatose (defined as unarousable unresponsiveness to external stimuli) should be considered as a candidate for TTM regardless of the initial presenting rhythm, and the decision to opt for targeted hypothermia versus targeted normothermia should be made on a case-by-case basis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:评估住院心脏骤停生存结局的骤停前临床决策工具的测试准确性。
    方法:我们搜索了Medline,Embase,和Cochrane图书馆从成立到2022年1月进行随机和非随机研究。我们使用诊断准确性研究框架的质量评估来评估偏倚风险,和建议评估的分级,开发和评估方法,以评估证据的确定性。我们报告敏感性,特异性,积极的预测结果,和预测生存结果的阴性预测结果。PROSPEROCRD42021268005。
    结果:我们检索了2517项研究,包括23项研究,使用13种不同的评分:12项研究调查8种不同的评分来评估生存结果,11项研究使用5种不同的评分来预测神经系统结果。所有均为历史队列/病例对照设计,仅包括成人。每个分数的测试准确性差异很大。在12项研究中,调查了8项不同的评分,评估出院/30天生存率,生存率预测的阴性预测值(NPV)从55.6%到100%不等.GO-FAR评分在7项研究中进行了评估,其中NPV的生存情况为大脑表现类别(CPC)1,范围为95.0%至99.2%。CPC≤2的两个评分评估生存率,这些评分未经外部验证。在所有预测分数中,证据的确定性被评为非常低。
    结论:我们在23项研究中发现了IHCA后13种不同的停搏前预测评分的不确定性非常低的证据。没有评分足够可靠以支持其在临床实践中的使用。我们没有发现儿童的证据。
    OBJECTIVE: To evaluate the test accuracy of pre-arrest clinical decision tools for in-hospital cardiac arrest survival outcomes.
    METHODS: We searched Medline, Embase, and Cochrane Library from inception through January 2022 for randomized and non-randomized studies. We used the Quality Assessment of Diagnostic Accuracy Studies framework to evaluate risk of bias, and Grading of Recommendations Assessment, Development and Evaluation methodology to evaluate certainty of evidence. We report sensitivity, specificity, positive predictive outcome, and negative predictive outcome for prediction of survival outcomes. PROSPERO CRD42021268005.
    RESULTS: We searched 2517 studies and included 23 studies using 13 different scores: 12 studies investigating 8 different scores assessing survival outcomes and 11 studies using 5 different scores to predict neurological outcomes. All were historical cohorts/ case control designs including adults only. Test accuracy for each score varied greatly. Across the 12 studies investigating 8 different scores assessing survival to hospital discharge/ 30-day survival, the negative predictive values (NPVs) for the prediction of survival varied from 55.6% to 100%. The GO-FAR score was evaluated in 7 studies with NPVs for survival with cerebral performance category (CPC) 1 ranging from 95.0% to 99.2%. Two scores assessed survival with CPC ≤ 2 and these were not externally validated. Across all prediction scores, certainty of evidence was rated as very low.
    CONCLUSIONS: We identified very low certainty evidence across 23 studies for 13 different pre-arrest prediction scores to outcome following IHCA. No score was sufficiently reliable to support its use in clinical practice. We identified no evidence for children.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    我们的目的是确定住院期间心脏骤停(IHCA)的心肺复苏(CPR)与出院后生活质量的关系。
    我们使用可用的数据库对IHCACPR前后的生活质量或功能结局进行了系统评价。所有筛选和数据抽象一式两份进行。
    我们筛选了10,927条记录,包括24篇代表20项独特研究的论文。15项研究测量了脑功能类别。生存率从11.8%到39.5%不等。出院后脑功能受损的风险范围为-16.1%(较低的风险)至存活至出院后脑功能不良的风险增加44.7%。四项研究测量了出院到机构环境,发现幸存者的风险增加了18.2-72.2%。一项研究测量了EQ-5D,发现CPR前后没有差异。一项研究测量了日常生活活动的表现,发现幸存者出院后需要更多活动的帮助。
    我们的审查受到对混杂因素缺乏调整的限制,包括每个结果的基线水平,在所有纳入的研究中。因此,虽然大多数结局的风险在出院后与入院前相比增加,但我们无法确定这是否是因果关系.
    Our aim was to determine the association of cardiopulmonary resuscitation (CPR) for in hospital cardiac arrest (IHCA) with quality of life after discharge.
    We performed a systematic review using available databases for studies that measured any quality-of-life or functional outcome both before and after CPR for IHCA. All screening and data abstraction was performed in duplicate.
    We screened 10,927 records and included 24 papers representing 20 unique studies. Fifteen studies measured Cerebral Performance Category. Survival ranged from 11.8% to 39.5%. The risk of impaired cerebral function after discharged ranged from -16.1% (lower risk) to 44.7% increased risk of poor cerebral function after surviving to discharge. Four studies measured discharge to an institutional environment finding that the risk was increased by 18.2-72.2% among survivors. One study measured EQ-5D and found no difference pre and post CPR. One study measured performance of activities of daily living finding that survivors needed assistance with more activities after discharge.
    Our review is limited by the lack of adjustment for confounders, including the baseline level of each outcome, in all included studies. Therefore, although risk for most outcomes was increased after discharge vs pre-admission we cannot be certain if this is a causal relationship.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:这项研究调查了是否与加压素联合治疗,类固醇,和肾上腺素(VSE)可改善院内心脏骤停(CA)复苏期间和之后的院内生存率和自主循环恢复(ROSC)。
    方法:从开始到2021年10月,对各种数据库进行了探索,以进行相关已发表的临床试验和队列研究。
    结果:纳入了三项临床试验。汇总分析表明,住院CA(IHCA)患者的VSE与ROSC增加显着相关(比值比(OR):2.281,95%置信区间(CI):1.304-3.989,P值=0.004)。两项研究(368例患者)的荟萃分析表明,心肺复苏期间和15-20分钟后平均动脉压(MAP)的降低存在显着差异(标准化平均差异(SMD):1.069,95%CI:0.851-1.288,P值<0.001),无肾功能衰竭天数(SMD=0.590;95%CI:0.312-0.869天;P值<0.001),和无凝血功能衰竭天数(SMD=0.403;95%CI:0.128-0.679,P值=0.004)。然而,生存率与出院率(OR:2.082,95%CI:0.638-6.796,P值=0.225)和无呼吸机天数(SMD=0.201,95%CI:-0.677,1.079天;P值=0.838)无显著差异.
    结论:IHCA期间和之后的VSE联合治疗可能在ROSC方面具有有益作用,肾和循环衰竭的自由天,地图。Prospero注册:CRD42020178297(05/07/2020)。
    BACKGROUND: This study investigated whether combination therapy with vasopressin, steroid, and epinephrine (VSE) improves in-hospital survival and return of spontaneous circulation (ROSC) during and after resuscitation in-hospital cardiac arrest (CA).
    METHODS: Various databases were explored from inception until October 2021 for relevant published clinical trials and cohort studies.
    RESULTS: Three clinical trials were included. Pooled analysis suggested that VSE was significantly associated with increased ROSC in patients with in-hospital CA (IHCA) (odds ratio (OR): 2.281, 95% confidence interval (CI): 1.304-3.989, P value = 0.004). Meta-analysis of two studies (368 patients) demonstrated a significant difference in the reduction of mean arterial pressure (MAP) during and 15-20 min after cardiopulmonary resuscitation (standardized mean difference (SMD): 1.069, 95% CI: 0.851-1.288, P value < 0.001), renal failure free days (SMD = 0.590; 95% CI: 0.312-0.869 days; P value < 0.001), and coagulation failure free days (SMD = 0.403; 95% CI: 0.128-0.679, P value = 0.004). However, no significant difference was observed for survival-to-discharge ratio (OR: 2.082, 95% CI: 0.638-6.796, P value = 0.225) and ventilator free days (SMD = 0.201, 95% CI: - 0.677, 1.079 days; P value = 0.838).
    CONCLUSIONS: VSE combination therapy during and after IHCA may have beneficial effects in terms of the ROSC, renal and circulatory failure free days, and MAP. Prospero registration: CRD42020178297 (05/07/2020).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    心脏骤停是美国发病率和死亡率的重要原因。心脏骤停可发生在社区或住院患者中。院内心脏骤停(IHCA)和院外心脏骤停之间有许多共同点;但是,存在显著差异。优化IHCA患者的预后取决于最佳可用证据支持的高质量护理。至关重要的是,重症监护护士必须熟悉与IHCA相关的证据。本文主要对IHCA的证据进行综述,重点关注重症监护护理实践的实际意义。
    Cardiac arrest is a significant cause of morbidity and mortality in the United States. Cardiac arrest can occur in the community or among hospitalized patients. There are many commonalities between in-hospital cardiac arrest (IHCA) and out-of-hospital cardiac arrest; however, significant differences exist. Optimizing outcomes for patients with IHCA depends on high-quality care supported by the best available evidence. It is essential that critical care nurses are familiar with the evidence related to IHCA. This article focuses on a review of the evidence on IHCA, focusing on practical implications for critical care nursing practice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    UNASSIGNED: To perform a review of the literature on the association between socioeconomic status and risk of and outcomes after in-hospital cardiac arrest.
    UNASSIGNED: PubMed and Embase were searched on January 24, 2020 for studies evaluating the association between socioeconomic status and risk of and/or outcomes after in-hospital cardiac arrest. Two reviewers independently screened the titles/abstracts and selected full texts for relevance. Data were extracted from included studies. Risk of bias was assessed using the Quality In Prognosis Studies (QUIPS) tool.
    UNASSIGNED: The literature search yielded 4960 unique records. We included nine studies evaluating the association between socioeconomic status and risk of and/or outcomes after in-hospital cardiac arrest. All studies were observational cohort studies, of which seven were from the USA. Seven studies were in an adult population, while two studies were in a pediatric population. Results were overall inconsistent although some studies found a higher in-hospital cardiac arrest incidence in patients from low-income communities. There was no clear association between other socioeconomic factors (i.e. education, occupation, marital status, and insurance) and risk of or outcomes after in-hospital cardiac arrest. Due to the scarcity and heterogeneity of available studies, meta-analyses were not performed.
    UNASSIGNED: There are limited data regarding the association between socioeconomic status and risk of and outcomes after in-hospital cardiac arrest and further research is warranted. Understanding the association between socioeconomic status and in-hospital cardiac arrest may reveal strategies to mitigate potential inequalities.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号